Report Overview

The UK Duchenne Muscular Dystrophy Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Duchenne Muscular Dystrophy, or DMD, is a debilitating genetic condition that causes a gradual loss of muscle function that affects everyday movements and activities. Muscular dystrophy is a condition that causes progressive wasting of the muscles. Duchenne muscular dystrophy is a particular type of muscular dystrophy caused by a mutation in the DMD gene. It affects more boys than girls. The DMD gene helps produce a protein called dystrophin, which is important for muscle strength, support, and repair. People with Duchenne muscular dystrophy dont produce the normal form of dystrophin, which means their muscles are more easily damaged and dont work properly. The genetic mutation of the DMD gene is either inherited from parents or caused by a genetic change in the child. This is the most common type affecting children.

DMD is caused by a genetic fault on the X chromosome and mainly affects boys because males only have one X chromosome. Females have two X chromosomes, so may carry the defective gene without showing any symptoms. It is usually recognized between three and six years of age. DMD is an X-linked recessive disorder caused by genetic variants in the dystrophin gene on the X chromosome. The incidence rate of DMD is 10.7 to 27.8 per 100,000 newborn males. In the UK, about 100 boys are born with DMD each year, and there are about 2,500 people living with the condition at any one time.



Market Growth Drivers

Major driving factors in the Duchenne Muscular Dystrophy marketare the introduction of novel drugs and therapies, disease-modifying therapies, strong support from various companies for drug development. Moreover, mutation-specific therapies are likely to emerge as a major breakthrough in the Duchenne muscular dystrophy treatment.

Drug developers are also focusing on developing new drugs and therapies targeting newborns, young infants, and also last-stage DMD patients. In the last few years, there has been rapid development in Duchenne muscular dystrophy therapeutics.

According to studies, the general deterioration in mental health in broad terms due to a variety of COVID-19 factors with feelings of anxiousness, disappointment, and rising frustration which is certainly a factor that will propel the DMD treatment market up.

Market Restraints

However, there is still a large number of patients who are not able to benefit from therapies and drugs due to its high cost and lack of awareness may hamper the DMD treatment market over the forecast period.